Solid Organ Transplantation From Hepatitis B Virus–Positive Donors: Consensus Guidelines for Recipient Management
| Autor: | Kevin M. Korenblat, Deepali Kumar, Darshana Dadhania, Benjamin L. Laskin, Michele I. Morris, Camille N. Kotton, J. P. Orlowski, K. Lu, Shirish Huprikar, Robin K. Avery, Josh Levitsky, Lara Danziger-Isakov, Vineeta Kumar, V. L. Venkat, Kevin C. Abbott, Erika D. Lease, Simon Horslen, Jennifer K McDermott, A. Mougdil, Christine E. Koval, Joseph Ahn, Emily A. Blumberg, Karen Doucette, Anjana Pillai, T. Mone, S. Naugler, Paolo Grossi, Kevin S. Brown, Roy D. Bloom |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
infection and infectious agents
Hepatitis B virus Tissue and Organ Procurement infectious disease Cost-Benefit Analysis medicine.medical_treatment Liver transplantation clinical research/practice medicine.disease_cause Antiviral Agents Immunity Medical medicine donors and donation: donor-derived infections Humans Immunology and Allergy Pharmacology (medical) Hepatitis B Antibodies Societies Medical Kidney transplantation Heart transplantation Transplantation business.industry Lamivudine Hepatitis B medicine.disease Hepatitis B Core Antigens Kidney Transplantation United States Tissue Donors Liver Transplantation viral: hepatitis B Heart Transplantation Immunology Societies business medicine.drug |
| Zdroj: | American Journal of Transplantation. 15:1162-1172 |
| ISSN: | 1600-6135 |
| DOI: | 10.1111/ajt.13187 |
| Popis: | Use of organs from donors testing positive for hepatitis B virus (HBV) may safely expand the donor pool. The American Society of Transplantation convened a multidisciplinary expert panel that reviewed the existing literature and developed consensus recommendations for recipient management following the use of organs from HBV positive donors. Transmission risk is highest with liver donors and significantly lower with non-liver (kidney and thoracic) donors. Antiviral prophylaxis significantly reduces the rate of transmission to liver recipients from isolated HBV core antibody positive (anti-HBc+) donors. Organs from anti-HBc+ donors should be considered for all adult transplant candidates after an individualized assessment of the risks and benefits and appropriate patient consent. Indefinite antiviral prophylaxis is recommended in liver recipients with no immunity or vaccine immunity but not in liver recipients with natural immunity. Antiviral prophylaxis may be considered for up to 1 year in susceptible non-liver recipients but is not recommended in immune non-liver recipients. Although no longer the treatment of choice in patients with chronic HBV, lamivudine remains the most cost-effective choice for prophylaxis in this setting. Hepatitis B immunoglobulin is not recommended. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text